2024 AANEM年会将着重介绍NMD药物第2b阶段对稀有神经肌肉疾病的NMD670试验。 2024 AANEM annual meeting will feature NMD Pharma's Phase 2b trial of NMD670 for rare neuromuscular diseases.
NMD药物A/S将在2024年AANEM年会上展示其罕见神经肌肉疾病的骨骼肌肉疗法。 NMD Pharma A/S will showcase its skeletal muscle therapy for rare neuromuscular diseases at the 2024 AANEM annual meeting. 介绍将重点介绍临床前和临床数据,重点是NMD670第2b阶段试验,这是针对氯-1氯化物信道的口服小分子抑制剂。 The presentation will feature preclinical and clinical data, focusing on its Phase 2b trial of NMD670, an oral small molecule inhibitor targeting the ClC-1 chloride channel. 这项双盲、安慰剂对照研究于 2024 年 6 月开始，评估其对全身性重症肌无力患者的影响。 This double-blind, placebo-controlled study began in June 2024, assessing its effects on generalized myasthenia gravis patients. 鼓励符合条件的病人在美国和欧洲参与。 Participation is encouraged for eligible patients in the US and Europe.